Literature DB >> 18493215

Effects on faecal microbiota of dietary and acidic oligosaccharides in children during partial formula feeding.

Fabien Magne1, Wahiba Hachelaf, Antonia Suau, Ghazalia Boudraa, Karim Bouziane-Nedjadi, Lionel Rigottier-Gois, Mahmoud Touhami, Jehan-François Desjeux, Philippe Pochart.   

Abstract

OBJECTIVE: To test the safety and effect on faecal microbiota of a formula with prebiotic oligosaccharides alone or in combination with acidic oligosaccharides in infants at the age of partial formula feeding. PATIENTS AND METHODS: The study was a double-blind, placebo-controlled, randomised intervention trial in which 82 healthy, full-term, partially breast-fed children, from 1 week to 3 months old, were given 1 of the following formulae: whey-based formula (control group), whey-based formula with galacto- and long-chain fructo-oligosaccharides (scGOS/lcFOS group), or whey-based formula with galacto- and long-chain fructo-oligosaccharides added with pectin-derived acidic oligosaccharides (scGOS/lcFOS/pAOS group). Children were studied for the duration of the partial formula feeding period and every 2 weeks for 2 months after breast-feeding cessation. The total bacteria count and the proportion of 7 bacterial families were determined using in situ hybridisation coupled to flow cytometry.
RESULTS: The total bacterial count did not alter with time or type of feeding (9.9 +/- 0.1 log10 cells per gram wet weight). Compared with the control group, there was an increase of the Bifidobacterium genus (P = 0.0001), and a decrease of proportions for the Bacteroides group (P = 0.02) and the Clostridium coccoides group (P = 0.01) in both oligosaccharide groups. The proportion of bifidobacteria was significantly higher in the scGOS/lcFOS/pAOS compared with the scGOS/lcFOS group (P < 0.01).
CONCLUSIONS: Infant formulae appear to be clinically safe and effective on infant microbiota. They minimize the alteration of faecal microbiota after cessation of breast-feeding and promote bifidobacteria proportions, with a stronger effect when acidic oligosaccharides are present.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493215     DOI: 10.1097/MPG.0b013e318164d920

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  10 in total

1.  Effect of a combination GOS/FOS® prebiotic mixture and interaction with calcium intake on mineral absorption and bone parameters in growing rats.

Authors:  Gabriel Bryk; Magalí Zeni Coronel; Gretel Pellegrini; Patricia Mandalunis; María Ester Rio; María Luz Pita Martín de Portela; Susana Noemí Zeni
Journal:  Eur J Nutr       Date:  2014-09-21       Impact factor: 5.614

2.  Functional metagenomic investigations of the human intestinal microbiota.

Authors:  Aimee M Moore; Christian Munck; Morten O A Sommer; Gautam Dantas
Journal:  Front Microbiol       Date:  2011-10-17       Impact factor: 5.640

3.  Faecal bifidobacteria in Indian neonates & the effect of asymptomatic rotavirus infection during the first month of life.

Authors:  Ramadass Balamurugan; Fabien Magne; Divya Balakrishnan; Antonia Suau; Sasirekha Ramani; Gagandeep Kang; Balakrishnan S Ramakrishna
Journal:  Indian J Med Res       Date:  2010-12       Impact factor: 2.375

4.  Partly Fermented Infant Formulae With Specific Oligosaccharides Support Adequate Infant Growth and Are Well-Tolerated.

Authors:  Frédéric Huet; Marieke Abrahamse-Berkeveld; Sebastian Tims; Umberto Simeoni; Gérard Beley; Christoph Savagner; Yvan Vandenplas; Jonathan O'B Hourihane
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-10       Impact factor: 2.839

5.  World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics.

Authors:  Alessandro Fiocchi; Ruby Pawankar; Carlos A Cuello-Garcia; Juan José Yepes-Nuñez; Gian Paolo Morgano; Yuan Zhang; Kangmo Ahn; Suleiman Al-Hammadi; Arnav Agarwal; Shreyas Gandhi; Kirsten Beyer; Wesley Burks; Giorgio W Canonica; Motohiro Ebisawa; Rose Kamenwa; Bee Wah Lee; Haiqi Li; Susan Prescott; John J Riva; Lanny Rosenwasser; Hugh Sampson; Michael Spigler; Luigi Terracciano; Andrea Vereda; Susan Waserman; Holger J Schünemann; Jan L Brożek
Journal:  World Allergy Organ J       Date:  2016-03-01       Impact factor: 4.084

Review 6.  The Potential of Pectins to Modulate the Human Gut Microbiota Evaluated by In Vitro Fermentation: A Systematic Review.

Authors:  Nélida Pascale; Fangjie Gu; Nadja Larsen; Lene Jespersen; Frederique Respondek
Journal:  Nutrients       Date:  2022-09-02       Impact factor: 6.706

Review 7.  Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review.

Authors:  Mary N Mugambi; Alfred Musekiwa; Martani Lombard; Taryn Young; Reneé Blaauw
Journal:  Nutr J       Date:  2012-10-04       Impact factor: 3.271

Review 8.  Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: a systematic review.

Authors:  Mary N Mugambi; Alfred Musekiwa; Martani Lombard; Taryn Young; Reneé Blaauw
Journal:  BMC Med Res Methodol       Date:  2013-11-13       Impact factor: 4.615

9.  Effects of Fructans from Mexican Agave in Newborns Fed with Infant Formula: A Randomized Controlled Trial.

Authors:  Gabriel López-Velázquez; Minerva Parra-Ortiz; Ignacio De la Mora-De la Mora; Itzhel García-Torres; Sergio Enríquez-Flores; Miguel Angel Alcántara-Ortigoza; Ariadna González-Del Angel; José Velázquez-Aragón; Rosario Ortiz-Hernández; José Manuel Cruz-Rubio; Pablo Villa-Barragán; Carlos Jiménez-Gutiérrez; Pedro Gutiérrez-Castrellón
Journal:  Nutrients       Date:  2015-10-29       Impact factor: 5.717

Review 10.  The Dietary Fiber Pectin: Health Benefits and Potential for the Treatment of Allergies by Modulation of Gut Microbiota.

Authors:  Frank Blanco-Pérez; Hanna Steigerwald; Stefan Schülke; Stefan Vieths; Masako Toda; Stephan Scheurer
Journal:  Curr Allergy Asthma Rep       Date:  2021-09-10       Impact factor: 4.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.